Sanofi Advances Amlitelimab Program With Key Drug-Interaction Study Completion

Sanofi (SNYNF) announced an update on their ongoing clinical study.

Sanofi’s latest study, “An Open-label, Drug-drug Interaction Study to Investigate the Effects of Amlitelimab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Participants With Moderate-to-severe Atopic Dermatitis,” looks at how its experimental drug amlitelimab interacts with common medicines. The goal is to confirm that amlitelimab does not cause meaningful changes in how key drugs are processed in the body, which is important for regulators and long term market use.

The trial tests amlitelimab, a subcutaneous injection also known as SAR445229, in adults with moderate to severe atopic dermatitis. It is given alongside a standard oral “cocktail” of cytochrome P450 probe drugs, including caffeine, metoprolol, midazolam, omeprazole, and warfarin, to check if amlitelimab affects their levels in the blood.

This is a Phase 1 interventional study with a single treatment group and no randomization. It is open label, meaning both doctors and patients know what is given, and the main purpose is treatment-focused, with a specific look at drug interaction risk rather than disease efficacy.

The study runs for up to 342 days per participant, with the active treatment period ending around Week 29 after the last amlitelimab dose at Week 25. Some participants may continue in a separate long term extension trial called RIVER-AD, which could extend safety and usage data and support future regulatory filings.

The trial was first submitted on Nov. 11, 2024, marking its formal entry into the clinical pipeline and signaling early stage development risk for investors. The latest update on Apr. 22, 2026, confirms the record is current, which matters for tracking timelines and reading this signal in the context of Sanofi’s broader immunology strategy.

The study is listed as completed, even though no detailed results have yet been posted, suggesting that data collection is done and analysis may be underway. Once full results appear, investors will look for a clean interaction profile, which would lower safety and label risk and support a smoother path to later stage trials and eventual commercialization.

For Sanofi, a favorable outcome would boost confidence in amlitelimab as a potential new option in the atopic dermatitis space, where it competes with names like Regeneron/Sanofi’s own Dupixent and other emerging biologics. A negative signal on drug interactions could slow development or lead to labeling limits, which in turn might mute upside in SNYNF relative to peers.

In the near term, the completion update alone is modestly positive, as it removes execution risk and keeps timelines on track for upcoming catalysts. Broader sentiment across immunology and dermatology remains constructive, so any later confirmation of a safe interaction profile could support a rerating of pipeline value for Sanofi and strengthen its position versus rival large cap pharma players.

Investors should watch for the posting of full Phase 1 data and any management commentary in earnings calls as the next key catalysts tied to this program. The amlitelimab drug interaction study is now completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about SNYNF’s potential, visit the Sanofi drug pipeline page.